Japan's Pharmaceutical Affairs and Food Sanitation Council's First Committee will review Takeda Pharmaceutical's glatiramer acetate drug approval application for relapsing multiple sclerosis on Aug. 28, a Ministry of Health, Labor and Welfare spokesman said.
Market-access contractor DKSH has signed a deal with Actelion Pharmaceuticals to help the company bolster its position in Asia.
Actelion has been prepping its new pulmonary arterial hypertension drug Opsumit to pick up the slack once the aging Tracleer goes off patent in November. And Opsumit seems poised for the job, raking in promising second-quarter numbers and prompting the company to boost its full-year guidance.
Switzerland-based Actelion is jumping into the vaccines industry by creating Vaxxilon, a startup that will focus on synthetic carbohydrate vaccines. It has licensed exclusive rights to multiple preclinical vaccines and other technologies from the Max Planck Society and will invest up to €30 million ($33 million), which will come in tranches over three to four years.
Actelion has got into startup creation. The Swiss biotech has committed €30 million ($33 million) to set up Vaxxilon, a synthetic carbohydrate vaccine-focused startup with a mission to push a program licensed from the Max Planck Society into the clinic within the next three years.
Acquisitive drugmaker Shire made a £12.4 billion ($18.9 billion) overture for Switzerland's Actelion, according to The Sunday Times, an offer that reportedly failed to entice the biotech's board.
Deal-hungry Shire hasn't snagged any new marketed drugs since bagging NPS Pharma in a deal it announced in January. But the rumor mill is churning again, and word has it it's set its sights on Actelion.
Actelion hasn't been too keen on becoming an M&A target lately. But if it's the one in the driver's seat? Bring on the deals, CFO André Muller says.
Fueled by strong sales for its latest cardio drug and a promising pipeline, Switzerland's Actelion says it's on the lookout for acquisitions but remains wary of paying the big premiums that have become commonplace in pharma.
Buoyed by the success of its PAH franchise, Switzerland's Actelion says it has begun a Phase III study of its in-house drug ponesimod for multiple sclerosis.